New antibody EA5 targets rare blood disorder PNH in early trial
Disease control
Recruiting now
This study tests a new drug called EA5 in 24 adults with paroxysmal nocturnal hemoglobinuria (PNH), a rare blood disease that destroys red blood cells. The main goal is to check if multiple doses of EA5 are safe and how the body processes it. This is an early-stage trial to gathe…
Phase: PHASE1 • Sponsor: Shanghai Lanyi Therapeutics Co., Ltd. • Aim: Disease control
Last updated May 15, 2026 11:56 UTC